Triple receptor negative breast cancer
Citation, DOI and article data
Triple receptor-negative (TRN) breast cancer or triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by a relative absence of immunohistochemical staining for the following hormone receptors/protein:
- estrogen receptor (OR)
- progesterone receptor (PR)
- human epidermal growth factor receptor 2 (HER2/neu)
TRN breast cancer represents 15-20% of all breast cancers 9. It is more likely to affect younger people and races such as African, Americans, Hispanics, and/or those with a BRCA1 gene mutation.
They have distinctive pathologic features, typically exhibiting a higher histologic grade, elevated mitotic count, central necrosis and fibrosis, pushing margins, scant stromal reaction, stromal lymphocytic response, and ductal or mixed histology with an overrepresentation of unusual histologies (metaplastic, medullary, or adenoid cystic carcinoma). It comprises of a heterogeneous group, encompassing at least two subcategories:
- basal subtype ~60%
- less well-defined non-basal/multiple marker negative subtype ~40%
TRN cancers were more frequently presented mammographically as a round, oval, or lobulated mass and were less frequently associated with calcifications than HER2+ / ER+ cancers. Less likely to demonstrate typical characteristics of malignancy, such as an irregular shape or spiculated margins 12. Associated ductal carcinoma in situ (DCIS) has also been reported at a much lower rate than HER2+, and ER+ patients.
Ultrasound features of smaller TRN breast cancer (<2 cm) have generally benign characteristics with a well-circumscribed margin and posterior acoustic enhancement, which are common in benign breast masses such as fibroadenomas ref.
One characteristic ultrasound feature which differentiates both is the roundness of the mass. TNBC tends to be more rounded than fibroadenomas ref. Other associated features in TRN breast cancer rather than in fibroadenomas are:
- associated edema
- skin thickening
- suspicious axillary lymphadenopathy
Larger TRN breast cancers (>2 cm) usually show the typical malignant features on ultrasound 10.
- T2 with fat suppression: intratumoral hyperintensity is common corresponds to abundant cytoplasm, edematous stroma and necrosis 11
- T1C+: rim enhancement is a specific sign that helps to differentiate small TRN breast cancers from benign lesions like fibroadenoma 11
Treatment and prognosis
Due to the absence of hormone receptors and HER-2, treatments like hormone therapy and other drugs which target estrogen, progesterone and HER-2 are ineffective. However, chemotherapy is considered to be an effective option in such cases with it responding earlier and better as compared to other breast malignancies.
Triple-negative breast cancer has the worst prognosis compared to other breast cancer with a more aggressive course and higher rates of recurrence 8.
- 1. Eurorad teaching files : Case 8532
- 2. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology. 2009;250 (3): 638-47. doi:10.1148/radiol.2503081054 - Pubmed citation
- 3. Dawood S, Broglio K, Esteva FJ et-al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann. Oncol. 2009;20 (4): 621-7. doi:10.1093/annonc/mdn682 - Free text at pubmed - Pubmed citation
- 4. Gluz O, Liedtke C, Gottschalk N et-al. Triple-negative breast cancer--current status and future directions. Ann. Oncol. 2009;20 (12): 1913-27. doi:10.1093/annonc/mdp492 - Pubmed citation
- 5. Choi YJ, Seong MH, Choi SH et-al. Ultrasound and clinicopathological characteristics of triple receptor-negative breast cancers. J Breast Cancer. 2011;14 (2): 119-23. doi:10.4048/jbc.2011.14.2.119 - Free text at pubmed - Pubmed citation
- 6. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16 Suppl 1 (Supplement 1): 1-11. doi:10.1634/theoncologist.2011-S1-01 - Pubmed citation
- 7. Krizmanich-Conniff KM, Paramagul C, Patterson SK et-al. Triple receptor-negative breast cancer: imaging and clinical characteristics. AJR Am J Roentgenol. 2012;199 (2): 458-64. doi:10.2214/AJR.10.6096 - Free text at pubmed - Pubmed citation
- 8. Ovcaricek T, Frkovic SG, Matos E et-al. Triple negative breast cancer - prognostic factors and survival. Radiol Oncol. 2011;45 (1): 46-52. doi:10.2478/v10019-010-0054-4 - Free text at pubmed - Pubmed citation
- 9. Min Sun Bae, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Han Suk Ryu, In-Ae Park, Jung Min Chang, Nariya Cho, Woo Kyung Moon. Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence. (2015) Radiology. 278 (2): 356-64. doi:10.1148/radiol.2015150089 - Pubmed
- 10. Yoon GY, Cha JH, Kim HH, Shin HJ, Chae EY, Choi WJ. Sonographic features that can be used to differentiate between small triple-negative breast cancer and fibroadenoma. (2018) Ultrasonography (Seoul, Korea). 37 (2): 149-156. doi:10.14366/usg.17036 - Pubmed
- 11. Angelini G, Marini C, Iacconi C, Mazzotta D, Moretti M, Picano E, Morganti R. Magnetic resonance (MR) features in triple negative breast cancer (TNBC) vs receptor positive cancer (nTNBC). (2018) Clinical imaging. 49: 12-16. doi:10.1016/j.clinimag.2017.10.016 - Pubmed
- 12. Janice S. Sung, Maxine S. Jochelson, Sandra Brennan, Sandra Joo, Yong H. Wen, Chaya Moskowitz, Junting Zheng, D David Dershaw, Elizabeth A. Morris. MR Imaging Features of Triple‐Negative Breast Cancers. (2013) The Breast Journal. 19 (6): 643. doi:10.1111/tbj.12182 - Pubmed